REFERENCES
- Westhuyzen J. The oxidation hypothesis of atherosclerosis: an update. Ann Clin Lab Sci 1997; 27: 1–10.
- Schwenke DC. Antioxidants and atherogenesis. J Nutr Biochem 1998; 9: 424–445.
- Berliner JA, Heinecke JW. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med 1996; 20: 707–727.
- Devaraj S, halal I. Oxidized low-density lipoprotein and atherosclerosis. Int J Clin Lab Res 1996; 26: 178–184.
- Esterbauer H, Dieber-Rotheneder M, Waeg G, Puhl H, Tatzber F. Endogenous antioxidants and lipoprotein oxidation. Biochem Soc Trans 1990: 18: 1059–1061.
- Jialal I, Vega GL, Grundy SM. Physiologic levels of ascorbate inhibit the oxidative modification of low density lipoprotein. Atherosclerosis 1990; 82: 185–191.
- Fuller CJ, Grundy SM, Norkus EP, halal I. Effect of ascorbate supplementation on low density lipoprotein oxidation in smokers. Atherosclerosis 1996; 119: 139–150.
- Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous monitoring of in vivo oxidation of human low density lipoprotein. Free Radic Res Commun 1989; 6: 67–75.
- halal I, Norkus EP, Cristol L, Grundy SM. Beta-carotene inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1993; 1086: 134–138.
- Noguchi N, Niki E. Dynamics of vitamin E action against LDL oxidation. Free Radic Res 1998; 28: 561–572.
- Gey FK. Vitamins E plus C and interacting conutrients required for optimal health. A critical and constructive review of epidemiology and supplementation data regarding cardiovascular disease and cancer. Biofactors 1998; 7: 113–174.
- Niki E, Noguchi N, Tsuchihashi H, Gotoh H. Interaction among vitamin C, vitamin E, and 13-carotene. Am J Clin Nutr 1995; 62 ( Suppl): 1322S-1326S.
- Fang JC, Kinlay S, Beltrame J et al. Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial. Lancet 2002; 359: 1108–1113.
- Hennekens CH, Gaziano JM, Manson JE, Buring JE. Antioxidant vitamin-cardiovascular disease hypothesis is still promising, but still unproven: the need for randomized trials. Am J Clin Nutr 1995; 62 ( Suppl): 1377S-1380S.
- Hercberg S, Galan P, Preziosi P et al. Background and rationale behind the SU.VI.MAX study, a prevention trial using nutritional doses of a combination of antioxidant vitamins and minerals to reduce cardiovascular diseases and cancers. Int J Vii' Nutr Res 1998; 68: 3–20.
- Allard JP, Royall D, Kurian R, Muggli R, Jeejeebhoy KN. Effects of beta-carotene supplementation on lipid peroxidation in humans. Am J Clin Nutr 1994; 59: 884–890.
- Wen Y, Cooke T, Feely J. The effect of pharmacological supplementation with vitamin C on low-density lipoprotein oxidation. Br J Clin Pharmacol 1997; 44: 94–97.
- Langlois M, Delanghe J. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 1996; 42: 1589–1600.
- Langlois MR, Delanghe JR, De Buyzere ML, Bernard DR, Ouyang J. Effect of haptoglobin on the metabolism of vitamin C. Am J Clin Nutr 1997; 66: 606–610.
- Delanghe J, Cambier B, Langlois M et al. Haptoglobin polymorphism, a genetic risk factor in coronary artery bypass surgery. Atherosclerosis 1997; 132: 215–219.
- Chapelle JP, Albert A, Smeets JP, Heusghem C, Kulbertus HE. Effect of the haptoglobin phenotype on the size of a myocardial infarct. N Engl J Med 1982; 307: 457–463.
- Delanghe J, Langlois M, Duprez D, De Buyzere M, Clement D. Haptoglobin polymorphism and peripheral arterial occlusive disease. Atherosclerosis 1999; 145: 287–292.
- Smithies O. Zone electrophoresis in starch gels: 300–485.
- Fink PC, Roemer M, Haeckel R et al. Measurement of proteins.
- Leonhardt W, Hanefeld M, Schaper F. Diminished susceptibility density lipoprotein. J Lipid Res 1995; 36: 2113–2128.
- Puhl H, Waeg H, Esterbauer H. Methods to determine oxidation of low-density proteins. Methods Enzymol 1994; 233: 425-441.patients with coronary disease: Cambridge Heart Antioxidant Study. Lancet 1996; 347: 781–786.
- Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K,Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study. Lancet 1996; 347: 781–786.
- The Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 2000; 432: 154–160.
- Melamed-Frank M, Lache O, Enav BI et al. Structure-function analysis of the antioxidant properties of haptoglobin. Blood 2001; 98: 3693–3698.
- Madsen M, Graversen JH, Moestrup SK. Haptoglobin and CD163: captor and receptor gating hemoglobin to macrophage lysosomes. Redox Report 2001; 6: 386–388.
- Graversen JH, Madsen M, Moestrup SK. CD163: a signal receptor scavenging haptoglobin-hemoglobin complexes from plasma. Int J Biochem Cell Biol 2002; 34: 309–314.
- Preziosi P, Galan P, Herbeth B et al. Effects of supplementation with a combination of antioxidant vitamins and trace elements, at nutritional doses, on biochemical indicators and markers of the antioxidant system in adult subjects. J Am Coll Nutr 1998; 17: 244–249.
- The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330: 1029–1035.